Harnessing Integrative Structural Biology Techniques Including NMR, X-Ray Crystallography, Cryo-EM, & Cryo-ET to Determine 3D Structures of Pharmacologically Relevant Targets & Propel Drug Design

This is your one-stop-shop for structure-based drug design to advance the exploration of 3D protein structures for drug discovery and development. Join the community as we delve into integrating direct and indirect methods to build the complete protein picture, evaluate how best to harness computational and AI methods to supercharge prediction and docking of proteins. Explore 20+ case study presentations to delve into how the structural biology toolbox has been applied to go after hard-to-drug proteins across small molecules, peptides, biologics, and vaccines. Across 3-days of immersive discussion, case studies, and networking the inaugural Structure-Based Drug Design Summit is set to set your structural biology team up for success.

What You Missed:

Shining a spotlight on the theoretical and practicalities of structural techniques including NMR, X-Ray Crystallography, and Cryo-EM, to maximize the opportunity in drug design, appreciating the strengths, limitations and complementary roles of the techniques with Servier, MD Anderson Center, Gilead, and Bayer

Diving into protein samples and strategies to mitigate obstacles and harness the potential of each protein to achieve higher resolution structures with Merck and Johnson & Johnson Innovative Medicine

Evaluating computational and predictive AI tools in structure prediction to assess the usability and efficacy of predicted structures in drug design with AbbVie

Dealing with hard-to-drug, dynamic proteins using the structural biology toolbox across small molecules, peptides, vaccines, and biologics, with Novartis, Pfizer, AstraZeneca, GSK, and UCB

Illuminating the emerging technologies, including Cryo-ET and time-resolved cryo-EM, in structure-based drug design to assess the potential in industry-based drug development with The Francis Crick Institute, Technical University Darmstadt, and Scripps Research Institute 

What Are the Speakers Looking Forward to?

“This meeting provides the ideal opportunity to network with colleagues in the industry and discuss the state-of-the-art in structure-based drug discovery. Having such a platform to present and talk about these techniques is invaluable in a very rapidly changing field”

Oliver Acton, Associate Principal Scientist – Cryo-EM, AstraZeneca

The meeting is an exceptional opportunity to meet experts and key opinion leaders with various relevant expertise and stimulate out-of-the box discussions”

Radoslav Enchev, Group Leader, The Francis Crick Institute

“Learning about state of the art structural biology techniques, connecting with drug discovery colleagues”

Henrik Moebitz, Associate Director – Data Science, Novartis 

“Attending the summit is a great way to network with peers as well as to strengthen existing relationship and most importantly to keep up with the latest development in the field of structure-based design of drugs”

Ilaria Ferlenghi, Associate Director, Head of Structural Vaccinology, GlaxoSmithKline